会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明授权
    • Quinoline derivatives as antibacterial agents
    • 喹啉衍生物作为抗菌剂
    • US07709498B2
    • 2010-05-04
    • US11296918
    • 2005-12-08
    • Koenraad Jozef Lodewijk Marcel AndriesAnil KoulJérôme Emile Georges GuillemontElisabeth Therese Jeanne Pasquier
    • Koenraad Jozef Lodewijk Marcel AndriesAnil KoulJérôme Emile Georges GuillemontElisabeth Therese Jeanne Pasquier
    • C07D215/38
    • C07D215/227A61K31/47A61K31/4709A61K31/496A61K31/497A61K31/501A61K31/506A61K31/53A61K31/5377A61K31/541C07D215/36C07D401/04C07D401/06C07D401/12C07D405/04C07D405/06C07D409/06Y02A50/473
    • The present invention relates to a method for the treatment of a bacterial infection comprising administering a therapeutically effective amount of a compound of formula or a pharmaceutically acceptable acid or base addition salt thereof, a stereochemically isomeric form thereof or a N-oxide form thereof, wherein R1 is hydrogen, halo, polyhaloC1-6alkyl, C1-6alkyl, Ar or Het; p is an integer equal to 1 or 2; R2 is C1-6alkyloxy, C1-6alkyloxyC1-6alkyloxy or C1-6alkylthio; R3 is Ar, Het or Het1; R4 and R5 each independently are hydrogen, C1-6alkyl or benzyl; or R4 and R5 together and including the N to which they are attached may form a radical selected from the group of pyrrolidinyl, 2-pyrrolinyl, 3-pyrrolinyl, pyrrolyl, imidazolidinyl, pyrazolidinyl, 2-imidazolinyl, 2-pyrazolinyl, imidazolyl, pyrazolyl, triazolyl, piperidinyl, pyridinyl, piperazinyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, morpholinyl and thiomorpholinyl, each of said rings may optionally be substituted with C1-6alkyl, halo, polyhaloC1-6alkyl, hydroxy, hydroxyC1-6alkyl, C1-6alkyloxy, amino, mono- or di(C1-6alkyl)amino, C1-6alkylthio, C1-6alkyloxyC1-6alkyl, C1-6alkylthioC1-6alkyl or pyrimidinyl; R6 is hydrogen, halo, polyhaloC1-6alkyl, C1-6alkyl, C1-6alkyloxy, C1-6alkylthio; or two vicinal R6 radicals may be taken together to form a bivalent radical of formula —CH═CH—CH═CH—; r is an integer equal to 1 or 2; R7 is hydrogen, C1-6alkyl, Ar, Het or Het1; provided that to bacterial infection is other than a Mycobacterial infection.
    • 本发明涉及一种治疗细菌感染的方法,包括给予治疗有效量的式的化合物或其药学上可接受的酸或碱加成盐,其立体化学异构形式或其N-氧化物形式,其中 R 1是氢,卤素,多卤代C 1-6烷基,C 1-6烷基,Ar或Het; p是等于1或2的整数; R2是C1-6烷氧基,C1-6烷氧基C1-6烷氧基或C1-6烷硫基; R3是Ar,Het或Het1; R 4和R 5各自独立地为氢,C 1-6烷基或苄基; 或R4和R5一起并且包括它们所连接的N可以形成选自吡咯烷基,2-吡咯啉基,3-吡咯啉基,吡咯基,咪唑烷基,吡唑烷基,2-咪唑啉基,2-吡唑啉基,咪唑基,吡唑基 三唑基,哌啶基,吡啶基,哌嗪基,哒嗪基,嘧啶基,吡嗪基,三嗪基,吗啉基和硫代吗啉基,每个所述环可任选被C 1-6烷基,卤素,多卤代C 1-6烷基,羟基,羟基C 1-6烷基,C 1-6烷氧基, 氨基,单或二(C 1-6烷基)氨基,C 1-6烷硫基,C 1-6烷氧基C 1-6烷基,C 1-6烷硫基C 1-6烷基或嘧啶基; R 6是氢,卤素,多卤代C 1-6烷基,C 1-6烷基,C 1-6烷氧基,C 1-6烷硫基; 或两个连位的R6基团可以一起形成式-CH = CH-CH = CH-的二价基团; r是等于1或2的整数; R7是氢,C1-6烷基,Ar,Het或Het1; 只要细菌感染不是分枝杆菌感染。
    • 4. 发明授权
    • Mycobacterial inhibitors
    • 分枝杆菌抑制剂
    • US07338949B2
    • 2008-03-04
    • US10596386
    • 2005-01-21
    • Jérôme Emile Georges GuillemontElisabeth Therese Jeanne Pasquier
    • Jérôme Emile Georges GuillemontElisabeth Therese Jeanne Pasquier
    • C07D413/06C07D413/14A61K31/5355A61P31/10
    • C07D413/06C07D413/14
    • The present invention relates to novel substituted quinoline derivatives according to the general formula (Ia) or the general formula (Ib) salts, quaternary amines, stereochemically isomeric forms, tautomeric forms and N-oxide forms thereof, wherein R1 is hydrogen, halo, haloalkyl, cyano, hydroxy, Ar, Het, alkyl, alkyloxy, alkylthio, alkyloxyalkyl, alkylthioalkyl, Ar-alkyl or di(Ar)alkyl; p is 1, 2, 3 or 4; R2 is hydrogen, hydroxy, thio, alkyloxy, alkyloxyalkyloxy, alkylthio, mono or di(alkyl)amino or a radical of formula R3 is alkyl, Ar, Ar-alkyl, Het or Het-alkyl; R4 is hydrogen, alkyl or benzyl; R5 is hydrogen, halo, haloalkyl, hydroxy, Ar, alkyl, alkyloxy, alkylthio, alkyloxyalkyl, alkylthioalkyl, Ar-alkyl or di(Ar)alkyl; or two vicinal R5 radicals may be taken together to form together with the phenyl ring to which they are attached a naphthyl; r is 1, 2, 3, 4 or 5; R6 is hydrogen, alkyl, Ar or Het; R7 is hydrogen or alkyl; R8 is oxo; or R7 and R8 taken together form the radical —CH═CH—N═; Z is CH2 or C(═O). The claimed compounds are useful for the treatment of mycobacterial diseases, particularly those diseases caused by pathogenic mycobacteria such as M. tuberculosis, M. bovis, M. avium, M. smegmatis and M. marinum. Also claimed is a pharmaceutical composition containing a compound of the present invention, the use of the claimed compounds or compositions for the manufacture of a medicament for the treatment of mycobacterial diseases and a process for preparing the claimed compounds.
    • 本发明涉及根据通式(Ia)或通式(Ib)的新的取代喹啉衍生物,其盐,季胺,立体化学异构形式,互变异构形式和N-氧化物形式,其中R 1, 烷基,烷氧基,烷硫基,烷氧基烷基,烷硫基烷基,芳烷基或二(Ar)烷基; p为1,2,3或4; R 2是氢,羟基,硫代,烷氧基,烷氧基烷氧基,烷硫基,一或二(烷基)氨基或式R 3的基团是烷基,Ar,Ar- 烷基,Het或Het-烷基; R 4是氢,烷基或苄基; R 5是氢,卤素,卤代烷基,羟基,Ar,烷基,烷氧基,烷硫基,烷氧基烷基,烷硫基烷基,芳烷基或二(Ar)烷基; 或两个邻位R 5个基团可以与它们所连接的苯环一起形成萘基; r为1,2,3,4或5; R 6是氢,烷基,Ar或Het; R 7是氢或烷基; R 8是氧代; 或R 7和R 8一起形成基团-CH-CH-N-; Z是CH 2或C(-O)。 所要求保护的化合物可用于治疗分枝杆菌疾病,特别是由致病性分枝杆菌引起的疾病如结核分枝杆菌,牛分枝杆菌,鸟分枝杆菌,耻垢分枝杆菌和马氏海马。 还要求保护的是含有本发明化合物,所要求保护的化合物或组合物在制备用于治疗分枝杆菌疾病的药物中的用途的药物组合物及其制备方法。
    • 6. 发明授权
    • Mycobacterial inhibitors
    • 分枝杆菌抑制剂
    • US07902225B2
    • 2011-03-08
    • US10596270
    • 2005-01-21
    • Jérôme Emile Georges GuillemontElisabeth Therese Jeanne PasquierDavid Francis Alain Lancois
    • Jérôme Emile Georges GuillemontElisabeth Therese Jeanne PasquierDavid Francis Alain Lancois
    • C07D215/38A61K31/04
    • C07D215/14C07D215/227C07D215/38C07D401/04C07D401/12C07D401/14C07D405/04C07D405/06C07D405/12C07D405/14C07D409/04C07D409/14
    • The present invention relates to novel substituted quinoline derivatives according to the general Formula (Ia) or the general Formula (Ib) the pharmaceutically acceptable acid or base addition salts thereof, the quaternary amines thereof, the stereochemically isomeric forms thereof the tautomeric forms thereof and the N-oxide forms thereof. The claimed compounds are useful for the treatment of mycobacterial diseases. In particular, compounds are claimed in which, independently from each other, R1 is halo; p=1; R2 is optionally substituted alkyloxy, alkyl, Ar, Het, or a radical of formula R3 is optionally substituted Ar or Het; q=1, R4 and R5 each independently are alkyl; R6 is hydrogen or a radical of formula r is equal to 0 or 1 and R7 is hydrogen or Ar. Also claimed is a composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of the claimed compounds, the use of the claimed compounds or compositions for the manufacture of a medicament for the treatment of mycobacterial diseases and a process for preparing the claimed compounds.
    • 本发明涉及根据通式(Ia)或通式(Ib)的新的取代喹啉衍生物,其药学上可接受的酸或碱加成盐,其季胺,其互变异构形式的立体化学异构形式和 N-氧化物形式。 所要求保护的化合物可用于治疗分枝杆菌病。 特别地,要求保护的化合物,其中R1彼此独立地为卤素; p = 1; R 2是任选取代的烷氧基,烷基,Ar,Het或式R3的基团是任选取代的Ar或Het; q = 1,R4和R5各自独立地为烷基; R6是氢或式r的基团等于0或1,而R7是氢或Ar。 还要求保护的是包含药学上可接受的载体和作为活性成分的治疗有效量的要求保护的化合物的组合物,所要求保护的化合物或组合物在制备用于治疗分枝杆菌疾病的药物中的用途以及制备方法 要求保护的化合物。